Emergent Biosolutions earnings missed by $0.23, revenue fell short of estimates
Emergent Biosolutions (EBS) reported Q3 EPS of -$0.64, missing estimates by $0.23, and revenue of $110M, below the $125.8M consensus. The stock is up 21.28% over 3 months but down 38.61% over 12 months. InvestingPro rates its financial health as 'great performance'.
How this was made
The 30-second read
Why it matters
The miss on both EPS and revenue is likely to drive near-term selling and increase scrutiny on subsequent quarters’ trajectory.
Market read
Traders can reassess EBS’s near-term earnings trajectory and risk premium based on the reported miss versus consensus.
What to watch
The piece does not include guidance, cash flow, or segment drivers, so traders may overreact to the headline EPS and revenue gap without knowing management’s outlook.
Background
This is a Q3 earnings report for Emergent Biosolutions, reported as an EPS and revenue miss versus analyst consensus.
Ticker impact
Emergent Biosolutions reported Q3 EPS of -$0.640, missing the -$0.410 estimate, and revenue of $110M vs $125.8M consensus.
Likely downside pressure as the market reprices the earnings power implied by the miss.
The article provides the company’s reported EPS and revenue versus consensus, which are direct drivers of post-earnings repricing.
Market effects
Biopharma/specialty biotech earnings misses can weigh on risk appetite for similar small/mid-cap names, but this is single-name specific.
Limited spillover beyond US small/mid-cap biotech sentiment.
Low, as the catalyst is company-specific earnings data.
Counterpoint
The article notes positive EPS revisions in the last 90 days, which could mean the miss is partly offset by improving forward expectations.
Key entities
- companyEmergent Biosolutions
Reported Q3 EPS of -$0.640 and revenue of $110M, both below consensus estimates.
